GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » EV-to-EBITDA

CGON (CG Oncology) EV-to-EBITDA : -14.72 (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CG Oncology's enterprise value is $1,412.06 Mil. CG Oncology's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-95.94 Mil. Therefore, CG Oncology's EV-to-EBITDA for today is -14.72.

The historical rank and industry rank for CG Oncology's EV-to-EBITDA or its related term are showing as below:

CGON' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.07   Med: -20   Max: -11.37
Current: -14.72

During the past 3 years, the highest EV-to-EBITDA of CG Oncology was -11.37. The lowest was -57.07. And the median was -20.00.

CGON's EV-to-EBITDA is ranked worse than
100% of 452 companies
in the Biotechnology industry
Industry Median: 9.27 vs CGON: -14.72

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-14), CG Oncology's stock price is $28.76. CG Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.294. Therefore, CG Oncology's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


CG Oncology EV-to-EBITDA Historical Data

The historical data trend for CG Oncology's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology EV-to-EBITDA Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -34.60 -19.00 -20.93

Competitive Comparison of CG Oncology's EV-to-EBITDA

For the Biotechnology subindustry, CG Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CG Oncology's EV-to-EBITDA falls into.



CG Oncology EV-to-EBITDA Calculation

CG Oncology's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1412.055/-95.936
=-14.72

CG Oncology's current Enterprise Value is $1,412.06 Mil.
CG Oncology's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-95.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CG Oncology  (NAS:CGON) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CG Oncology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.76/-1.294
=At Loss

CG Oncology's share price for today is $28.76.
CG Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.294.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


CG Oncology EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CG Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology Headlines

From GuruFocus